Overview

SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias

Status:
Withdrawn
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and tolerability of SP-420 and it's efficacy in terms of lowering iron in subjects with Beta-thalassemia or other rare anemias who need regular blood transfusions.
Phase:
Phase 2
Details
Lead Sponsor:
Abfero Pharmaceuticals, Inc